Cogstate Beheer

Beheer criteriumcontroles 3/4

De CEO Cogstate is Brad O'Connor, benoemd in Dec2005, heeft een ambtstermijn van 18.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.23M, bestaande uit 31.2% salaris en 68.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 3.15% van de aandelen van het bedrijf, ter waarde A$ 5.38M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 4 jaar.

Belangrijke informatie

Brad O'Connor

Algemeen directeur

US$1.2m

Totale compensatie

Percentage CEO-salaris	31.2%
Dienstverband CEO	18.9yrs
Eigendom CEO	3.1%
Management gemiddelde ambtstermijn	3.8yrs
Gemiddelde ambtstermijn bestuur	4yrs

Recente managementupdates

Recent updates

Pinning Down Cogstate Limited's (ASX:CGS) P/E Is Difficult Right Now

Aug 30

There's Been No Shortage Of Growth Recently For Cogstate's (ASX:CGS) Returns On Capital

Jul 26

Growth Investors: Industry Analysts Just Upgraded Their Cogstate Limited (ASX:CGS) Revenue Forecasts By 11%

Mar 23

Earnings Update: Cogstate Limited (ASX:CGS) Just Reported And Analysts Are Trimming Their Forecasts

Mar 02

Cogstate Limited (ASX:CGS) Shares Could Be 19% Below Their Intrinsic Value Estimate

Jan 13

Investors Appear Satisfied With Cogstate Limited's (ASX:CGS) Prospects As Shares Rocket 51%

Oct 04

Do Cogstate's (ASX:CGS) Earnings Warrant Your Attention?

Sep 28

Returns On Capital Are A Standout For Cogstate (ASX:CGS)

Sep 02

We Ran A Stock Scan For Earnings Growth And Cogstate (ASX:CGS) Passed With Ease

Jun 30

Investors Should Be Encouraged By Cogstate's (ASX:CGS) Returns On Capital

Mar 22

We Think Some Shareholders May Hesitate To Increase Cogstate Limited's (ASX:CGS) CEO Compensation

Oct 20

Cogstate (ASX:CGS) Is Looking To Continue Growing Its Returns On Capital

Jul 23

Is Cogstate (ASX:CGS) Using Too Much Debt?

Apr 29

What Can The Trends At Cogstate (ASX:CGS) Tell Us About Their Returns?

Mar 14

Here's What Cogstate Limited's (ASX:CGS) Shareholder Ownership Structure Looks Like

Feb 21

How Much Is Cogstate's (ASX:CGS) CEO Getting Paid?

Jan 17

Can You Imagine How Jubilant Cogstate's (ASX:CGS) Shareholders Feel About Its 214% Share Price Gain?

Dec 05

Analyse CEO-vergoeding

Hoe is Brad O'Connor's beloning veranderd ten opzichte van Cogstate's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	US$1m	US$385k	US$5m
Mar 31 2024	n/a	n/a	US$5m
Dec 31 2023	n/a	n/a	US$6m
Sep 30 2023	n/a	n/a	US$5m
Jun 30 2023	US$1m	US$363k	US$4m
Mar 31 2023	n/a	n/a	US$4m
Dec 31 2022	n/a	n/a	US$3m
Sep 30 2022	n/a	n/a	US$6m
Jun 30 2022	US$2m	US$346k	US$8m
Mar 31 2022	n/a	n/a	US$9m
Dec 31 2021	n/a	n/a	US$10m
Sep 30 2021	n/a	n/a	US$7m
Jun 30 2021	US$1m	US$344k	US$5m
Mar 31 2021	n/a	n/a	US$3m
Dec 31 2020	n/a	n/a	US$335k
Sep 30 2020	n/a	n/a	-US$811k
Jun 30 2020	US$931k	US$371k	-US$2m
Mar 31 2020	n/a	n/a	-US$3m
Dec 31 2019	n/a	n/a	-US$3m
Sep 30 2019	n/a	n/a	-US$3m
Jun 30 2019	US$655k	US$368k	-US$2m
Mar 31 2019	n/a	n/a	-US$2m
Dec 31 2018	n/a	n/a	-US$1m
Sep 30 2018	n/a	n/a	-US$907k
Jun 30 2018	US$783k	US$338k	-US$566k

Compensatie versus markt: De totale vergoeding ($USD 1.23M ) Brad } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 296.04K ).

Compensatie versus inkomsten: De vergoeding van Brad is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Brad O'Connor

18.9yrs

Tenure

US$1,232,152

Compensatie

Mr. Bradley John O'Connor, also known as Brad, B.Bus, CA, has been the Chief Executive Officer and Managing Director of Cogstate Limited since December 1, 2005 and served as its Chief Financial Officer sin...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Bradley O'Connor	CEO, MD & Executive Director	18.9yrs	US$1.23m	3.15% A$ 5.4m
Darren Watson	Chief Financial Officer	3.8yrs	US$497.19k	geen gegevens
Rachel Colite	Executive VP of Clinical Trials	1.4yrs	US$495.76k	0.11% A$ 184.8k
Paul Maruff	Founder & Chief Innovation Officer	no data	geen gegevens	geen gegevens
Kristi Geddes	General Counsel	1.6yrs	geen gegevens	geen gegevens
Kenneth Billard	Chief Commercial Officer	5yrs	US$436.14k	geen gegevens
Kaycee Sink	Chief Medical Officer	less than a year	geen gegevens	geen gegevens
David Franks	Joint Company Secretary	3.8yrs	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van CGS wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Bradley O'Connor	CEO, MD & Executive Director	18.9yrs	US$1.23m	3.15% A$ 5.4m
Kristi Geddes	General Counsel	no data	geen gegevens	geen gegevens
Richard van den Broek	Independent Non-Executive Director	14.3yrs	US$57.96k	2.58% A$ 4.4m
Martyn Myer	Non-Executive Chairman	24.9yrs	US$95.67k	13.74% A$ 23.5m
Ingrid Player	Independent Non-Executive Director	5.3yrs	US$71.76k	0.078% A$ 132.8k
Kim Wenn	Independent Non-Executive Director	4yrs	US$64.92k	0.0073% A$ 12.5k
Richard Mohs	Independent Non-Executive Director	7.8yrs	US$64.78k	0.039% A$ 66.3k
Sharon Cohen	Member of Scientific Advisory Board	2.4yrs	geen gegevens	geen gegevens
Eric Siemers	Distinguished Medical Adviser & Chairman of Scientific Advisory Board	2.4yrs	geen gegevens	geen gegevens
Bruce Albala	Member of Scientific Advisory Board	2.4yrs	geen gegevens	geen gegevens
Adam Brickman	Member of Scientific Advisory Board	2.4yrs	geen gegevens	geen gegevens
Kate Papp	Member of Scientific Advisory Board	2.4yrs	geen gegevens	geen gegevens

4.0yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CGS wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).

Cogstate Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Cogstate Appoints Kaycee Sink as Chief Medical Officer

CEO, MD & Executive Director exercised options to buy AU$965k worth of stock.

Non-Executive Chairman recently bought AU$108k worth of stock

CEO, MD & Executive Director recently bought AU$100k worth of stock

Cogstate Limited Announces Resignation of David Dolby as Non-Executive Director

High number of new and inexperienced directors

Recent updates

Cogstate Appoints Kaycee Sink as Chief Medical Officer

CEO, MD & Executive Director exercised options to buy AU$965k worth of stock.

New minor risk - Market cap size

Pinning Down Cogstate Limited's (ASX:CGS) P/E Is Difficult Right Now

Non-Executive Chairman recently bought AU$108k worth of stock

Full year 2024 earnings: EPS exceeds analyst expectations

Cogstate Limited Provides Financial Guidance for the Fiscal Year 2025

Consensus revenue estimates decrease by 10%, EPS upgraded

There's Been No Shortage Of Growth Recently For Cogstate's (ASX:CGS) Returns On Capital

If EPS Growth Is Important To You, Cogstate (ASX:CGS) Presents An Opportunity

First half 2024 earnings released: EPS: US$0.012 (vs US$0 in 1H 2023)

Price target decreased by 8.1% to AU$1.70

Investor sentiment deteriorates as stock falls 17%

The Price Is Right For Cogstate Limited (ASX:CGS)

Cogstate Limited to Report First Half, 2024 Results on Feb 22, 2024

Price target increased by 8.6% to AU$1.85

Cogstate Limited Provides Revenue Guidance for 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Is Cogstate Limited (ASX:CGS) Trading At A 29% Discount?

Now 21% undervalued

Price target decreased by 9.0% to AU$1.70

Now 23% undervalued

Cogstate Limited Provides Revenue Guidance in the Fourth Quarter 2023

Consensus EPS estimates increase by 12%

Returns Are Gaining Momentum At Cogstate (ASX:CGS)

Growth Investors: Industry Analysts Just Upgraded Their Cogstate Limited (ASX:CGS) Revenue Forecasts By 11%

Consensus revenue estimates increase by 11%

Investor sentiment deteriorates as stock falls 16%

CEO, MD & Executive Director recently bought AU$100k worth of stock

Earnings Update: Cogstate Limited (ASX:CGS) Just Reported And Analysts Are Trimming Their Forecasts

First half 2023 earnings released: EPS: US$0 (vs US$0.024 in 1H 2022)

Consensus EPS estimates increase by 23%, revenue downgraded

Investor sentiment deteriorates as stock falls 25%

Now 24% undervalued

Cogstate Limited to Report Fiscal Year 2023 Results on Aug 17, 2023

Now 22% undervalued

Cogstate Limited Announces Resignation of David Dolby as Non-Executive Director

Cogstate Limited (ASX:CGS) Shares Could Be 19% Below Their Intrinsic Value Estimate

Price target decreased to AU$1.92

High number of new and inexperienced directors

Investors Appear Satisfied With Cogstate Limited's (ASX:CGS) Prospects As Shares Rocket 51%

Do Cogstate's (ASX:CGS) Earnings Warrant Your Attention?

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Returns On Capital Are A Standout For Cogstate (ASX:CGS)

Price target decreased to AU$2.18

Full year 2022 earnings: EPS misses analyst expectations

Price target decreased to AU$2.41

Cogstate Limited Provides Earnings Guidance for the Fiscal Year 2023

High number of new and inexperienced directors

Price target decreased to AU$2.43

Investor sentiment improved over the past week

High number of new and inexperienced directors

We Ran A Stock Scan For Earnings Growth And Cogstate (ASX:CGS) Passed With Ease

Cogstate Announces Formation of Scientific Advisory Board

Consensus EPS estimates fall by 82%

Investor sentiment improved over the past week

Investors Should Be Encouraged By Cogstate's (ASX:CGS) Returns On Capital

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

We Think Some Shareholders May Hesitate To Increase Cogstate Limited's (ASX:CGS) CEO Compensation

Independent Non-Executive Director exercised options to buy AU$244k worth of stock.

Non-Executive Chairman recently sold AU$89k worth of stock

Non-Executive Chairman exercised options and sold AU$188k worth of stock

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS US$0.031 (vs US$0.008 loss in FY 2020)

Insider recently sold AU$1.8m worth of stock

Cogstate (ASX:CGS) Is Looking To Continue Growing Its Returns On Capital

Insider recently sold AU$1.3m worth of stock